James Parsons Net Worth

The estimated Net Worth of James T. Parsons is at least $171 Thousand dollars as of 8 January 2021. Mr. Parsons owns over 8,505 units of DiaMedica Therapeutics stock worth over $37,252 and over the last 6 years he sold DMAC stock worth over $0. In addition, he makes $134,123 as Director at DiaMedica Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Parsons DMAC stock SEC Form 4 insiders trading

James has made over 2 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 8,505 units of DMAC stock worth $61,576 on 8 January 2021.

The largest trade he's ever made was exercising 8,505 units of DiaMedica Therapeutics stock on 8 January 2021 worth over $61,576. On average, James trades about 896 units every 63 days since 2018. As of 8 January 2021 he still owns at least 8,505 units of DiaMedica Therapeutics stock.

You can see the complete history of Mr. Parsons stock trades at the bottom of the page.

James Parsons biography

James T. Parsons, CPA., CA., is Director of the Company. He was Corporate Secretary of the Company. He joined company as Corporate Secretary of DiaMedica Inc. He resigned from the position of Vice President - Finance of the Company with effect from 15 January 2015. Mr. Parsons joined DiaMedica in October 2010 with an background in the life sciences industry and over 20 years of financial management experience. Prior to joining DiaMedica, Mr. Parsons was the Chief Financial Officer and Corporate Secretary for Amorfix Life Sciences Ltd. where his responsibilities included finance, administration, contract management, and corporate governance. Mr. Parsons has been a CFO in the life sciences industry since 2000 with early-stage to late-clinical stage biotechnology companies across many diagnostic and therapeutic service areas. He is also currently the Chief Financial Officer of Stem Cell Therapeutics Corp since August 2011. Mr. Parsons has a Master of Accounting degree from the University of Waterloo.

What is the salary of James Parsons?

As the Director of DiaMedica Therapeutics, the total compensation of James Parsons at DiaMedica Therapeutics is $134,123. There are 4 executives at DiaMedica Therapeutics getting paid more, with Dietrich John Pauls MBA having the highest compensation of $687,579.

What's James Parsons's mailing address?

James's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.

Insiders trading at DiaMedica Therapeutics

Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg, and David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.

What does DiaMedica Therapeutics do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Complete history of Mr. Parsons stock trades at Trillium Therapeutics Inc and DiaMedica Therapeutics

DiaMedica Therapeutics executives and stock owners

DiaMedica Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich John Pauls MBA,
  Pres, CEO & Director
• Rick Pauls,
  President, Chief Executive Officer, Director
• Dr. Harry W. Alcorn Jr., Pharm.D.,
  Sr. VP of Clinical Operations
• Scott B. Kellen C.A.,
  CFO & Company Sec.
• James Parsons,
  Director
• Michael Giuffre,
  Independent Director
• Jerry Xiao,
  Director
• Harry Alcorn,
  Director
• Paul Papi,
  Vice President - Business Development
• Sydney Gilman,
  Vice President - Regulatory Affairs
• Scott Kellen,
  Chief Financial Officer, Corporate Secretary
• Richard Pilnik,
  Independent Chairman of the Board
• Dr. Edward G. Calamai Ph.D.,
  Consulting Head of Manufacturing
• Tanya Lewis,
  Director
• David J. Wambeke,
  Chief Business Officer
• Jantrill Ab Stahlberg,
  
• Dietrich John Pauls,
  President and CEO
• Zhenyu Xiao,
  Director
• Todd A. Verdoorn,
  Chief Scientific Officer
• Koch Thomas Tom Enterprise ...,
  
• Koch Thomas Tom Enterprise ...,
  
• Charles Pauling Semba,
  Director
• Amy L. Burroughs,
  Director
• Kirsten L Gruis,
  Chief Medical Officer
• Dominic R Cundari,
  Chief Commercial Officer
• Julie Van Orsdel Daves,
  SVP Clinical Development Oper.
• Masuoka K. Lorianne,
  Chief Medical Officer
• Richard Kuntz,
  Director